What Is Microcin? Definition and What Research Reports

Definition

Microcin is the name given to a family of small, ribosomally synthesised and post-translationally modified antibacterial peptides — conventionally those below roughly 10 kilodaltons — that are produced by Gram-negative bacteria of the order Enterobacterales, most commonly Escherichia coli and its relatives, and that inhibit or kill closely related bacterial strains competing for the same niche. The term is a category label, not a single molecule: individual members are distinguished by letters or numbers (microcin B17, microcin C7, microcin J25, microcin Y, microcin E492, Mcc1229), and they differ substantially in chemistry, in the receptors they exploit to enter target cells, and in the intracellular targets they act on. In short, a microcin is a bacterially made peptide antibiotic encoded by a gene cluster that also carries a self-immunity function protecting the producing cell.

What Class of Molecule Is a Microcin?

Microcins are gene-encoded peptides, which separates them from non-ribosomal peptide antibiotics assembled by enzyme assembly lines. A precursor peptide is translated, then tailored by dedicated maturation enzymes, then exported. Because the backbone is genetically encoded, the sequences are readily traced in genome data, and researchers describe them alongside other ribosomally synthesised and post-translationally modified peptides (RiPPs).

The family is traditionally split into two classes based on size and modification:

A 2022 comparative genomics analysis reported evidence that class II microcin gene clusters are widespread across Enterobacterales genomes, including in genomes not previously flagged as microcin producers (PMID 36394322). Genetic context matters too: a 2024 sequencing study reported the complete nucleotide sequence of pMccB17, the plasmid that carries the microcin B17 biosynthetic genes, and compared it with related plasmids (PMID 38440924).

Where Microcins Come From

Microcins originate from bacteria themselves, typically from strains living in the mammalian gut where competition for iron and carbon is intense. Production is usually encoded on a plasmid or a chromosomal island containing the precursor gene, modification enzymes, an export pump and an immunity gene. The 2024 pMccB17 analysis described that plasmid-borne architecture for microcin B17 in detail (PMID 38440924). Producers are not limited to E. coli: a 2024 report characterised a microcin from Vibrio cholerae, describing its antibacterial action, a proteolysis-based immunity mechanism in the producing organism, and activity in an in vivo model (PMID 39260372).

Maturation is enzymatic. A 2017 structural study examined TldD/E, the protease involved in processing microcin precursors, and reported on the structural basis for its substrate specificity (PMID 28943336).

How the Term Is Used in Peptide Research

In the literature, "microcin" is used in three fairly distinct ways.

• As a taxonomic label for a peptide family. Papers on genome mining use it to classify clusters, as in the 2022 survey of class II microcins across Enterobacterales (PMID 36394322).
• As a named model compound. Microcin J25 is one of the most studied lasso peptides in structural chemistry; a 2019 mass spectrometry study reported evidence of cis/trans isomerisation at Pro7 and Pro16 in microcin J25 (PMID 30834511).
• As a candidate antibacterial scaffold. Studies test named microcins against pathogens in culture and in animals, as with the 2024 report that microcin C7 inhibited growth of Porphyromonas gingivalis and improved periodontal status in a rat model (PMID 39349994).

It is worth noting that "microcin" in this literature refers to bacterial antibacterial peptides. It is not a human therapeutic peptide category, and the term should not be confused with unrelated research peptides that share a superficially similar name.

Lasso Peptides Within the Family

Several microcins adopt a lasso topology — a threaded, knot-like fold that resists heat and proteolysis. A 2021 discovery paper described microcin Y as a novel lasso peptide and reported its bioactivity (PMID 34314160). Stability under digestive conditions has been examined directly: a 2018 study reported on the fate and retained biological activity of the lasso peptide microcin J25 under simulated gastrointestinal tract conditions (PMID 30123205).

What the Published Literature Reports

Across the cited body of work, researchers have concentrated on four questions: how microcins get into target cells, what they do once inside, how stable they are, and what happens in living hosts.

Uptake and Targets

Microcins commonly hijack outer-membrane nutrient transporters. A 2022 study of Mcc1229 reported that the microcin required the catecholate siderophore receptor CirA for activity and that it amplified Stx2a production, and it reported that the microcin was produced in vivo (PMID 34871041). Work on microcin Y implicated the FhuA outer-membrane receptor and the inner-membrane transporter SbmA in susceptibility, with a 2026 study describing an FhuA–SbmA-driven resistance pathway in Salmonella Typhimurium (PMID 41519334).

Activity in Models

The 2024 Vibrio cholerae microcin paper reported antibacterial action together with in vivo activity and a proteolytic immunity mechanism in the producer (PMID 39260372). In a dental context, the study of microcin C7 reported inhibition of P. gingivalis growth and improvement in periodontal status in rats (PMID 39349994). A 2024 paper on microcin J25 reported antibacterial effects in infection models alongside a proposed non-microbial mechanism involving differential regulation of dopaminergic receptors (PMID 39533384).

Unusual Biophysics

Not every finding is antibacterial. A 2017 report described prion-like characteristics of the bacterial protein microcin E492, adding an amyloid-related dimension to how this molecule behaves (PMID 28361921).

Resistance and Off-Target Consequences: What Studies Report

Because microcins depend on specific transporters, loss or alteration of those transporters can confer resistance. The 2026 Salmonella Typhimurium study reported that an FhuA–SbmA-driven resistance pathway to microcin Y was accompanied by transcriptomic reprogramming and enhanced virulence in that organism (PMID 41519334). A second example of an unwanted downstream consequence was reported for Mcc1229, which amplified Shiga toxin Stx2a production (PMID 34871041). These are microbiological observations in bacterial and animal systems, not human safety data; no human adverse-event data for microcins appear in the papers cited here.

Limits of the Evidence

The published microcin literature is overwhelmingly bacteriological, structural and preclinical. It describes genome surveys (PMID 36394322), plasmid sequences (PMID 38440924), enzyme structures (PMID 28943336), peptide conformation (PMID 30834511), digestive stability (PMID 30123205) and animal infection models (PMID 39349994). Findings in rodents, cell culture or bacterial genetics do not translate automatically to humans, and no microcin discussed in these papers is an approved human medicine. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or treatment decision.

References

• Antibacterial action, proteolytic immunity, and in vivo activity of a Vibrio cholerae microcin (Cell Host & Microbe, 2024)
• Complete nucleotide sequence and comparative genomic analysis of microcin B17 plasmid pMccB17 (MicrobiologyOpen, 2024)
• Discovery and Bioactivity of the Novel Lasso Peptide Microcin Y (Journal of Agricultural and Food Chemistry, 2021)
• The Origins of Specificity in the Microcin-Processing Protease TldD/E (Structure, 2017)
• FhuA-SbmA-driven resistance pathway to microcin Y triggers transcriptomic reprogramming and virulence enhancement in Salmonella Typhimurium (International Journal of Biological Macromolecules, 2026)
• Prion-like characteristics of the bacterial protein Microcin E492 (Scientific Reports, 2017)
• Evidence for Widespread Class II Microcins in Enterobacterales Genomes (Applied and Environmental Microbiology, 2022)
• The antimicrobial peptide Microcin C7 inhibits the growth of Porphyromonas gingivalis and improves the periodontal status in a rat model (Journal of Applied Microbiology, 2024)
• Fate and Biological Activity of the Antimicrobial Lasso Peptide Microcin J25 Under Gastrointestinal Tract Conditions (Frontiers in Microbiology, 2018)
• Evidence of Cis/Trans-Isomerization at Pro7/Pro16 in the Lasso Peptide Microcin J25 (Journal of the American Society for Mass Spectrometry, 2019)
• Mcc1229, an Stx2a-Amplifying Microcin, Is Produced In Vivo and Requires CirA for Activity (Infection and Immunity, 2022)
• Bacteriocin Microcin J25's antibacterial infection effects and novel non-microbial regulatory mechanisms: differential regulation of dopaminergic receptors (Journal of Animal Science and Biotechnology, 2024)